N-Lipidated Peptide Dimers: Effective Antibacterial Agents against Gram-Negative Pathogens through Lipopolysaccharide Permeabilization

Journal of Medicinal Chemistry

Volumn 58, Issue 16, 2015, Pages 6533-6548

  Koh, Jun Jie ^a,b   Lin, Huifen ^a   Caroline, Vonny ^a   Chew, Yu Siang ^a   Pang, Li Mei ^a,f   Aung, Thet Tun ^a   Li, Jianguo ^a,e   Lakshminarayanan, Rajamani ^a,d   Tan, Donald T H ^b,c   Verma, Chandra ^a,e,f,g   Tan, Ai Ling ^h   Beuerman, Roger W ^a,d   Liu, Shouping ^a,d  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e BIOINFORMATICS INSTITUTE   (Singapore)

^f NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^g NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^h SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIUM LIPOPOLYSACCHARIDE; DIMER; FATTY ACID; N LIPIDATED PEPTIDE DIMER; POLYMYXIN B; POLYMYXIN B NONAPEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG; CARBAPENEM DERIVATIVE; LACTATE DEHYDROGENASE; LIPOPEPTIDE; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL OUTER MEMBRANE; BACTERIAL VIABILITY; BACTERICIDAL ACTIVITY; BIOCOMPATIBILITY; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CELL MEMBRANE; CELL PERMEABILIZATION; CELL VIABILITY; CONJUGATION; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GRAM NEGATIVE BACTERIUM; HEMOLYSIS; MEMBRANE PERMEABILITY; MIC90; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; ANIMAL; ANTIBIOTIC RESISTANCE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; ENTEROBACTERIACEAE; FEMALE; FIBROBLAST; HUMAN; IN VITRO STUDY; MALE; METABOLISM; MICROBIAL SENSITIVITY TEST; PERMEABILITY; RABBIT; SYNTHESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CELL MEMBRANE; CELL SURVIVAL; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; FATTY ACIDS; FEMALE; FIBROBLASTS; GRAM-NEGATIVE BACTERIA; HEMOLYSIS; HUMANS; IN VITRO TECHNIQUES; L-LACTATE DEHYDROGENASE; LIPOPEPTIDES; LIPOPOLYSACCHARIDES; MALE; MICE; MICROBIAL SENSITIVITY TESTS; PERMEABILITY; RABBITS;

EID: 84940676066     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00628     Document Type: Article

References (78)

1. Levy, S. B.; Marshall, B. Antibacterial resistance worldwide: causes, challenges and responses Nat. Med. 2004, 10, S122-129 10.1038/nm1145
2. Walkty, A.; Adam, H.; Baxter, M.; Denisuik, A.; Lagace-Wiens, P.; Karlowsky, J. A.; Hoban, D. J.; Zhanel, G. G. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012 Antimicrob. Agents Chemother. 2014, 58, 2554-2563 10.1128/AAC.02744-13
3. Knappe, D.; Piantavigna, S.; Hansen, A.; Mechler, A.; Binas, A.; Nolte, O.; Martin, L. L.; Hoffmann, R. Oncocin (VDKPPYLPRPRPPRRIYNR-NH2): a novel antibacterial peptide optimized against gram-negative human pathogens J. Med. Chem. 2010, 53, 5240-5247 10.1021/jm100378b
4. Hidron, A. I.; Edwards, J. R.; Patel, J.; Horan, T. C.; Sievert, D. M.; Pollock, D. A.; Fridkin, S. K. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007 Infect. Control Hosp. Epidemiol. 2008, 29, 996-1011 10.1086/591861
5. Schwaber, M. J.; Carmeli, Y. Carbapenem-resistant Enterobacteriaceae: a potential threat JAMA 2008, 300, 2911-2913 10.1001/jama.2008.896
6. Nikaido, H. Prevention of drug access to bacterial targets: permeability barriers and active efflux Science 1994, 264, 382-388 10.1126/science.8153625
7. Delcour, A. H. Outer membrane permeability and antibiotic resistance Biochim. Biophys. Acta, Proteins Proteomics 2009, 1794, 808-816 10.1016/j.bbapap.2008.11.005
8. Singh, S.; Kalle, M.; Papareddy, P.; Schmidtchen, A.; Malmsten, M. Lipopolysaccharide interactions of C-terminal peptides from human thrombin Biomacromolecules 2013, 14, 1482-1492 10.1021/bm400150c
9. Vaara, M. Agents that increase the permeability of the outer membrane Microbiol. Rev. 1992, 56, 395-411
10. Mohanram, H.; Bhattacharjya, S. Resurrecting inactive antimicrobial peptides from the lipopolysaccharide trap Antimicrob. Agents Chemother. 2014, 58, 1987-1996 10.1128/AAC.02321-13
11. Fischbach, M. A.; Walsh, C. T. Antibiotics for emerging pathogens Science 2009, 325, 1089-1093 10.1126/science.1176667
12. Zasloff, M. Antimicrobial peptides of multicellular organisms Nature 2002, 415, 389-395 10.1038/415389a
13. Hancock, R. E.; Lehrer, R. Cationic peptides: a new source of antibiotics Trends Biotechnol. 1998, 16, 82-88 10.1016/S0167-7799(97)01156-6
14. Schmidtchen, A.; Pasupuleti, M.; Malmsten, M. Effect of hydrophobic modifications in antimicrobial peptides Adv. Colloid Interface Sci. 2014, 205, 265-274 10.1016/j.cis.2013.06.009
15. Liu, S.; Zhou, L.; Li, J.; Suresh, A.; Verma, C.; Foo, Y. H.; Yap, E. P.; Tan, D. T.; Beuerman, R. W. Linear analogues of human beta-defensin 3: concepts for design of antimicrobial peptides with reduced cytotoxicity to mammalian cells ChemBioChem 2008, 9, 964-973 10.1002/cbic.200700560
16. Bai, Y.; Liu, S.; Li, J.; Lakshminarayanan, R.; Sarawathi, P.; Tang, C.; Ho, D.; Verma, C.; Beuerman, R. W.; Pervushin, K. Progressive structuring of a branched antimicrobial peptide on the path to the inner membrane target J. Biol. Chem. 2012, 287, 26606-26617 10.1074/jbc.M112.363259
17. Bai, Y.; Liu, S.; Jiang, P.; Zhou, L.; Li, J.; Tang, C.; Verma, C.; Mu, Y.; Beuerman, R. W.; Pervushin, K. Structure-dependent charge density as a determinant of antimicrobial activity of peptide analogues of defensin Biochemistry 2009, 48, 7229-7239 10.1021/bi900670d
18. Zhou, L.; Liu, S. P.; Chen, L. Y.; Li, J.; Ong, L. B.; Guo, L.; Wohland, T.; Tang, C. C.; Lakshminarayanan, R.; Mavinahalli, J.; Verma, C.; Beuerman, R. W. The structural parameters for antimicrobial activity, human epithelial cell cytotoxicity and killing mechanism of synthetic monomer and dimer analogues derived from hBD3 C-terminal region Amino Acids 2011, 40, 123-133 10.1007/s00726-010-0565-8
19. Vaara, M. Novel derivatives of polymyxins J. Antimicrob. Chemother. 2013, 68, 1213-1219 10.1093/jac/dkt039
20. Jerala, R.; Porro, M. Endotoxin neutralizing peptides Curr. Top. Med. Chem. 2004, 4, 1173-1184 10.2174/1568026043388079
21. Danner, R. L.; Joiner, K. A.; Rubin, M.; Patterson, W. H.; Johnson, N.; Ayers, K. M.; Parrillo, J. E. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide Antimicrob. Agents Chemother. 1989, 33, 1428-1434 10.1128/AAC.33.9.1428
22. Zou, H.; Koh, J. J.; Li, J.; Qiu, S.; Aung, T. T.; Lin, H.; Lakshminarayanan, R.; Dai, X.; Tang, C.; Lim, F. H.; Zhou, L.; Tan, A. L.; Verma, C.; Tan, D. T.; Chan, H. S.; Saraswathi, P.; Cao, D.; Liu, S.; Beuerman, R. W. Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity J. Med. Chem. 2013, 56, 2359-2373 10.1021/jm301683j
23. Koh, J. J.; Lin, S.; Aung, T. T.; Lim, F.; Zou, H.; Bai, Y.; Li, J.; Lin, H.; Pang, L. M.; Koh, W. L.; Salleh, S. M.; Lakshminarayanan, R.; Zhou, L.; Qiu, S.; Pervushin, K.; Verma, C.; Tan, D. T.; Cao, D.; Liu, S.; Beuerman, R. W. Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections J. Med. Chem. 2015, 58, 739-752 10.1021/jm501285x
24. Kratz, F.; Ehling, G.; Kauffmann, H. M.; Unger, C. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin Hum. Exp. Toxicol. 2007, 26, 19-35 10.1177/0960327107073825
25. Pini, A.; Giuliani, A.; Falciani, C.; Fabbrini, M.; Pileri, S.; Lelli, B.; Bracci, L. Characterization of the branched antimicrobial peptide M6 by analyzing its mechanism of action and in vivo toxicity J. Pept. Sci. 2007, 13, 393-399 10.1002/psc.858
26. McDuff, F. O.; Doucet, A.; Beauregard, M. Low concentration of guanidine hydrochloride induces the formation of an aggregation-prone state in alpha-urease Biochem. Cell Biol. 2004, 82, 305-313 10.1139/o03-072
27. Monticelli, L.; Kandasamy, S. K.; Periole, X.; Larson, R. G.; Tieleman, D. P.; Marrink, S.-J. The MARTINI Coarse-Grained Force Field: Extension to Proteins J. Chem. Theory Comput. 2008, 4, 819-834 10.1021/ct700324x
28. Bjelkmar, P.; Larsson, P.; Cuendet, M. A.; Hess, B.; Lindahl, E. Implementation of the CHARMM Force Field in GROMACS: Analysis of Protein Stability Effects from Correction Maps, Virtual Interaction Sites, and Water Models J. Chem. Theory Comput. 2010, 6, 459-466 10.1021/ct900549r
29. Helander, I. M.; Mattila-Sandholm, T. Fluorometric assessment of gram-negative bacterial permeabilization J. Appl. Microbiol. 2000, 88, 213-219 10.1046/j.1365-2672.2000.00971.x
30. Wu, M.; Hancock, R. E. Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane J. Biol. Chem. 1999, 274, 29-35 10.1074/jbc.274.1.29
31. Koh, J. J.; Qiu, S.; Zou, H.; Lakshminarayanan, R.; Li, J.; Zhou, X.; Tang, C.; Saraswathi, P.; Verma, C.; Tan, D. T.; Tan, A. L.; Liu, S.; Beuerman, R. W. Rapid bactericidal action of alpha-mangostin against MRSA as an outcome of membrane targeting Biochim. Biophys. Acta, Biomembr. 2013, 1828, 834-844 10.1016/j.bbamem.2012.09.004
32. Oo, T. Z.; Cole, N.; Garthwaite, L.; Willcox, M. D.; Zhu, H. Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection J. Antimicrob. Chemother. 2010, 65, 1243-1251 10.1093/jac/dkq106
33. Rotem, S.; Radzishevsky, I.; Mor, A. Physicochemical properties that enhance discriminative antibacterial activity of short dermaseptin derivatives Antimicrob. Agents Chemother. 2006, 50, 2666-2672 10.1128/AAC.00030-06
34. Malina, A.; Shai, Y. Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide Biochem. J. 2005, 390, 695-702 10.1042/BJ20050520
35. Lockwood, N. A.; Haseman, J. R.; Tirrell, M. V.; Mayo, K. H. Acylation of SC4 dodecapeptide increases bactericidal potency against Gram-positive bacteria, including drug-resistant strains Biochem. J. 2004, 378, 93-103 10.1042/BJ20031393
36. The White House National Action Plan for Combating Antibiotic-Resistant Bacteria. https://www.whitehouse.gov/sites/default/files/docs/national-action-plan-for-combating-antiboticresistant-bacteria.pdf accessed April 8
37. Miller, K. A.; Suresh Kumar, E. V.; Wood, S. J.; Cromer, J. R.; Datta, A.; David, S. A. Lipopolysaccharide sequestrants: structural correlates of activity and toxicity in novel acylhomospermines J. Med. Chem. 2005, 48, 2589-2599 10.1021/jm049449j
38. David, S. A.; Silverstein, R.; Amura, C. R.; Kielian, T.; Morrison, D. C. Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria Antimicrob. Agents Chemother. 1999, 43, 912-919
39. Andra, J.; Garidel, P.; Majerle, A.; Jerala, R.; Ridge, R.; Paus, E.; Novitsky, T.; Koch, M. H.; Brandenburg, K. Biophysical characterization of the interaction of Limulus polyphemus endotoxin neutralizing protein with lipopolysaccharide Eur. J. Biochem. 2004, 271, 2037-2046 10.1111/j.1432-1033.2004.04134.x
40. Brandenburg, K.; Jurgens, G.; Andra, J.; Lindner, B.; Koch, M. H.; Blume, A.; Garidel, P. Biophysical characterization of the interaction of high-density lipoprotein (HDL) with endotoxins Eur. J. Biochem. 2002, 269, 5972-5981 10.1046/j.1432-1033.2002.03333.x
41. Alakomi, H. L.; Paananen, A.; Suihko, M. L.; Helander, I. M.; Saarela, M. Weakening effect of cell permeabilizers on gram-negative bacteria causing biodeterioration Appl. Environ. Microbiol. 2006, 72, 4695-4703 10.1128/AEM.00142-06
42. Wenzel, M.; Chiriac, A. I.; Otto, A.; Zweytick, D.; May, C.; Schumacher, C.; Gust, R.; Albada, H. B.; Penkova, M.; Kramer, U.; Erdmann, R.; Metzler-Nolte, N.; Straus, S. K.; Bremer, E.; Becher, D.; Brotz-Oesterhelt, H.; Sahl, H. G.; Bandow, J. E. Small cationic antimicrobial peptides delocalize peripheral membrane proteins Proc. Natl. Acad. Sci. U. S. A. 2014, 111, E1409-1418 10.1073/pnas.1319900111
43. Chongsiriwatana, N. P.; Wetzler, M.; Barron, A. E. Functional synergy between antimicrobial peptoids and peptides against Gram-negative bacteria Antimicrob. Agents Chemother. 2011, 55, 5399-5402 10.1128/AAC.00578-11
44. Chu-Kung, A. F.; Nguyen, R.; Bozzelli, K. N.; Tirrell, M. Chain length dependence of antimicrobial peptide-fatty acid conjugate activity J. Colloid Interface Sci. 2010, 345, 160-167 10.1016/j.jcis.2009.11.057
45. Japelj, B.; Zorko, M.; Majerle, A.; Pristovsek, P.; Sanchez-Gomez, S.; de Tejada, G.M.; Moriyon, I.; Blondelle, S. E.; Brandenburg, K.; Andra, J.; Lohner, K.; Jerala, R. The acyl group as the central element of the structural organization of antimicrobial lipopeptide J. Am. Chem. Soc. 2007, 129, 1022-1023 10.1021/ja067419v
46. Makovitzki, A.; Avrahami, D.; Shai, Y. Ultrashort antibacterial and antifungal lipopeptides Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 15997-16002 10.1073/pnas.0606129103
47. Lin, B. F.; Missirlis, D.; Krogstad, D. V.; Tirrell, M. Structural effects and lipid membrane interactions of the pH-responsive GALA peptide with fatty acid acylation Biochemistry 2012, 51, 4658-4668 10.1021/bi300314h
48. Radzishevsky, I. S.; Rotem, S.; Zaknoon, F.; Gaidukov, L.; Dagan, A.; Mor, A. Effects of acyl versus aminoacyl conjugation on the properties of antimicrobial peptides Antimicrob. Agents Chemother. 2005, 49, 2412-2420 10.1128/AAC.49.6.2412-2420.2005
49. Shankar, S. S.; Benke, S. N.; Nagendra, N.; Srivastava, P. L.; Thulasiram, H. V.; Gopi, H. N. Self-assembly to function: design, synthesis, and broad spectrum antimicrobial properties of short hybrid E-vinylogous lipopeptides J. Med. Chem. 2013, 56, 8468-8474 10.1021/jm400884w
50. Majerle, A.; Kidric, J.; Jerala, R. Enhancement of antibacterial and lipopolysaccharide binding activities of a human lactoferrin peptide fragment by the addition of acyl chain J. Antimicrob. Chemother. 2003, 51, 1159-1165 10.1093/jac/dkg219
51. Marynka, K.; Rotem, S.; Portnaya, I.; Cogan, U.; Mor, A. In vitro discriminative antipseudomonal properties resulting from acyl substitution of N-terminal sequence of dermaseptin s4 derivatives Chem. Biol. 2007, 14, 75-85 10.1016/j.chembiol.2006.11.009
52. Andra, J.; Lohner, K.; Blondelle, S. E.; Jerala, R.; Moriyon, I.; Koch, M. H.; Garidel, P.; Brandenburg, K. Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin-derived peptide Biochem. J. 2005, 385, 135-143 10.1042/BJ20041270
53. David, S. A.; Awasthi, S. K.; Balaram, P. The role of polar and facial amphipathic character in determining lipopolysaccharide-binding properties in synthetic cationic peptides J. Endotoxin Res. 2000, 6, 249-256 10.1179/096805100101532117
54. David, S. A. Towards a rational development of anti-endotoxin agents: novel approaches to sequestration of bacterial endotoxins with small molecules J. Mol. Recognit. 2001, 14, 370-387 10.1002/jmr.549
55. Brandenburg, K.; Jurgens, G.; Muller, M.; Fukuoka, S.; Koch, M. H. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin Biol. Chem. 2001, 382, 1215-1225 10.1515/BC.2001.152
56. Andra, J.; Koch, M. H.; Bartels, R.; Brandenburg, K. Biophysical characterization of endotoxin inactivation by NK-2, an antimicrobial peptide derived from mammalian NK-lysin Antimicrob. Agents Chemother. 2004, 48, 1593-1599 10.1128/AAC.48.5.1593-1599.2004
57. Hancock, R. E. Cationic peptides: effectors in innate immunity and novel antimicrobials Lancet Infect. Dis. 2001, 1, 156-164 10.1016/S1473-3099(01)00092-5
58. Shalev, D. E.; Rotem, S.; Fish, A.; Mor, A. Consequences of N-acylation on structure and membrane binding properties of dermaseptin derivative K4-S4-(1-13) J. Biol. Chem. 2006, 281, 9432-9438 10.1074/jbc.M513051200
59. Giacometti, A.; Cirioni, O.; Ghiselli, R.; Mocchegiani, F.; Orlando, F.; Silvestri, C.; Bozzi, A.; Di Giulio, A.; Luzi, C.; Mangoni, M. L.; Barra, D.; Saba, V.; Scalise, G.; Rinaldi, A. C. Interaction of antimicrobial peptide temporin L with lipopolysaccharide in vitro and in experimental rat models of septic shock caused by gram-negative bacteria Antimicrob. Agents Chemother. 2006, 50, 2478-2486 10.1128/AAC.01553-05
60. Jerala, R. Synthetic lipopeptides: a novel class of anti-infectives Expert Opin. Invest. Drugs 2007, 16, 1159-1169 10.1517/13543784.16.8.1159
61. Biswas, S.; Brunel, J. M.; Dubus, J. C.; Reynaud-Gaubert, M.; Rolain, J. M. Colistin: an update on the antibiotic of the 21st century Expert Rev. Anti-Infect. Ther. 2012, 10, 917-934 10.1586/eri.12.78
62. Lopez-Fabal, F.; Culebras, E.; Bonilla, I.; Gomez, M.; Picazo, J. J. In vitro activities of colistin combinations against Pseudomonas aeruginosa isolated from the intensive care unit Rev. Esp. Quimioter. 2008, 21, 189-193
63. Timurkaynak, F.; Can, F.; Azap, O. K.; Demirbilek, M.; Arslan, H.; Karaman, S. O. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units Int. J. Antimicrob. Agents 2006, 27, 224-228 10.1016/j.ijantimicag.2005.10.012
64. Landman, D.; Bratu, S.; Alam, M.; Quale, J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B J. Antimicrob. Chemother. 2005, 55, 954-957 10.1093/jac/dki153
65. Tascini, C.; Gemignani, G.; Ferranti, S.; Tagliaferri, E.; Leonildi, A.; Lucarini, A.; Menichetti, F. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections J. Chemother. 2004, 16, 282-287 10.1179/joc.2004.16.3.282
66. Gunderson, B. W.; Ibrahim, K. H.; Hovde, L. B.; Fromm, T. L.; Reed, M. D.; Rotschafer, J. C. Synergistic activity of colistin and ceftazidime against multiantibiotic-resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model Antimicrob. Agents Chemother. 2003, 47, 905-909 10.1128/AAC.47.3.905-909.2003
67. Wu, Y. L.; Scott, E. M.; Po, A. L.; Tariq, V. N. Ability of azlocillin and tobramycin in combination to delay or prevent resistance development in Pseudomonas aeruginosa J. Antimicrob. Chemother. 1999, 44, 389-392 10.1093/jac/44.3.389
68. Arnusch, C. J.; Branderhorst, H.; de Kruijff, B.; Liskamp, R. M.; Breukink, E.; Pieters, R. J. Enhanced membrane pore formation by multimeric/oligomeric antimicrobial peptides Biochemistry 2007, 46, 13437-13442 10.1021/bi7015553
69. Liu, Z.; Deshazer, H.; Rice, A. J.; Chen, K.; Zhou, C.; Kallenbach, N. R. Multivalent antimicrobial peptides from a reactive polymer scaffold J. Med. Chem. 2006, 49, 3436-3439 10.1021/jm0601452
70. Dagan, A.; Efron, L.; Gaidukov, L.; Mor, A.; Ginsburg, H. In vitro antiplasmodium effects of dermaseptin S4 derivatives Antimicrob. Agents Chemother. 2002, 46, 1059-1066 10.1128/AAC.46.4.1059-1066.2002
71. Hurdle, J. G.; O'Neill, A. J.; Chopra, I.; Lee, R. E. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections Nat. Rev. Microbiol. 2011, 9, 62-75 10.1038/nrmicro2474
72. Apisarnthanarak, A.; Hsu, L. Y.; Khawcharoenporn, T.; Mundy, L. M. Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings? Expert Rev. Anti-Infect. Ther. 2013, 11, 147-157 10.1586/eri.12.164
73. Gupta, N.; Limbago, B. M.; Patel, J. B.; Kallen, A. J. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention Clin. Infect. Dis. 2011, 53, 60-67 10.1093/cid/cir202
74. Queenan, A. M.; Bush, K. Carbapenemases: the versatile beta-lactamases Clin. Microbiol. Rev. 2007, 20, 440-458 10.1128/CMR.00001-07
75. Yigit, H.; Queenan, A. M.; Anderson, G. J.; Domenech-Sanchez, A.; Biddle, J. W.; Steward, C. D.; Alberti, S.; Bush, K.; Tenover, F. C. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae Antimicrob. Agents Chemother. 2001, 45, 1151-1161 10.1128/AAC.45.4.1151-1161.2001
76. Teo, J. W. P.; Tan, P.; La, M.-V.; Krishnan, P.; Tee, N.; Koh, T. H.; Deepak, R. N.; Tan, T. Y.; Jureen, R.; Lin, R. T. P. Surveillance trends of carbapenem-resistant Enterobacteriaceae from Singapore, 2010-2013 J. Glob. Antimicrob. Resist. 2014, 2, 99-102 10.1016/j.jgar.2013.11.003
77. Patel, G.; Huprikar, S.; Factor, S. H.; Jenkins, S. G.; Calfee, D. P. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies Infect. Control Hosp. Epidemiol. 2008, 29, 1099-1106 10.1086/592412
78. Schwaber, M. J.; Klarfeld-Lidji, S.; Navon-Venezia, S.; Schwartz, D.; Leavitt, A.; Carmeli, Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality Antimicrob. Agents Chemother. 2008, 52, 1028-1033 10.1128/AAC.01020-07